Status:
COMPLETED
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
Lead Sponsor:
Second Affiliated Hospital of Nanchang University
Conditions:
Vernal Keratoconjunctivitis
Cyclosporine 0.05% Eye Drops
Eligibility:
All Genders
12-21 years
Phase:
PHASE1
Brief Summary
To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing...
Detailed Description
Vernal keratoconjunctivitis (VKC) is an allergic disease that severely affects the eyesight of adolescents. Vernal keratoconjunctivitis (VKC) usually occurs in temperate regions such as the Mediterran...
Eligibility Criteria
Inclusion
- Inclusion criteria
- patients had a noticeable seasonal, and recurrent Itching, Discomfort(burning, stinging, and foreign body sensation), Photophobia and tears, Viscous discharge;
- Slit-lamp microscopy showed Conjunctival Hyperemia, Tarsal papillary, Limbal hypertrophy, Horner-Trantas dots, Keratitis in some patients;
- No other medication history in recent 2 weeks;
- Patients have high compliance and are willing to take drugs on time and return to the clinic in time
- Exclusion criteria:
- with other related immune diseases or other drug use history in recent 2 weeks;
- Patients with evident and severe organic diseases or mental diseases;
- Low compliance, unable to take drugs on time or fail to return to the clinic on time.
Exclusion
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05353101
Start Date
July 1 2020
End Date
June 1 2021
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330000